Research Analysts Offer Predictions for Evommune Q3 Earnings

Evommune, Inc. (NYSE:EVMN) – William Blair issued their Q3 2025 EPS estimates for shares of Evommune in a report released on Monday, December 1st. William Blair analyst M. Phipps expects that the company will post earnings of ($12.16) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Evommune’s Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.32) EPS, FY2026 earnings at ($2.35) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.89) EPS and FY2029 earnings at ($3.89) EPS.

Several other analysts also recently weighed in on EVMN. Evercore ISI began coverage on Evommune in a research note on Monday. They set an “outperform” rating and a $40.00 target price on the stock. Wall Street Zen upgraded shares of Evommune to a “hold” rating in a research note on Thursday, November 20th. Morgan Stanley assumed coverage on shares of Evommune in a report on Monday. They issued an “overweight” rating and a $36.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Evommune in a research note on Monday. They set an “overweight” rating on the stock. Finally, Leerink Partners assumed coverage on shares of Evommune in a research report on Monday. They set an “outperform” rating and a $42.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $39.33.

Evommune Stock Performance

Shares of NYSE:EVMN opened at $21.16 on Wednesday. Evommune has a 52 week low of $16.70 and a 52 week high of $24.03.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.